Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ:ATAI)

1.470 +0.050 (+3.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Psychedelic Stock Gainers And Losers From March 27, 2023
Via Benzinga
Expert Ratings for ATAI Life Sciences
Via Benzinga
ATAI Life Sciences Earnings Perspective: Return On Capital Employed
Via Benzinga
GH Research, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Atai Life Sciences Hopes Hercules Can Help 'Sustain' Operations Until 2026
Biopharma company Atai Life Sciences' (NASDAQ: ATAI) fourth quarter and full year 2022 consolidated financial results show: 
Via Benzinga
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
From atai Life Sciences
Via GlobeNewswire
The Latest Analyst Ratings for ATAI Life Sciences
Via Benzinga
Atai Layoffs 2023: What to Know About the Latest ATAI Job Cuts
Atai Life Sciences has just announced 30% job cuts. Here's how investors should be interpreting the Atai layoffs as ATAI stock rises. 
Via InvestorPlace
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From March 22, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From March 21, 2023
Via Benzinga
EXCLUSIVE: NYC Ketamine Center Co-Founder On Prices, Insurance, Competition & Expansion
This is the third article of a three-part series, you can find the first and 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 20, 2023
Via Benzinga
An Update On The Performance Of The 7 Largest Psychedelic Stocks
The 7 largest psychedelic drug stocks are ranked as to their stock performances since the beginning of March and year-to-date, their likelihood of financial distress, analyst price forecasts and the... 
Via Talk Markets
The "Rags-To-Riches" Portfolio: An Update
Cannabis, psychedelic, and plant-based food stocks performed extremely poorly in 2022, down 73% vs. 2021 but perhaps some of them will bounce back with major returns in 2023. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From March 17, 2023
Via Benzinga
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's morning session saw 84 companies set new 52-week lows. 
Via Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
Via Benzinga
Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll... 
Via Benzinga
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From March 9, 2023
Via Benzinga
Numinus Wellness, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From March 6, 2023
Via Benzinga
Atai Update: Ketamine Trials Are Ongoing, Company Cuts 30% Workforce
The clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) founded in 2018 shared updates on the two clinical trials as well as its plan to streamline its workforce with significant... 
Via Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.